Supreme flexibility of the Kaptas concept
For the pharmaceutical industry, quick market access of products is crucial. The concept created by Kaptas Oy enables competitiveness of the pharmaceutical industry in the sensitive early phase of product development and production. With its expertise, Kaptas has earned the trust of the pharmaceutical industry from prototype series to mass production.
Competitiveness with a flexible concept
Due to the Kaptas concept, pharmaceutical companies can schedule their investments in the mass production of assembly in a safe and cost-effective manner.
The concept enables a significant competitive edge for the pharmaceutical industry
The assembly lines can be scaled when the volumes of the customer increase; realised annual production volumes total 1–20 million pieces (BX, Spider, Slimline, Highspeed).
The product can be produced in the critical early phase as cost-effectively as possible all the way until the potential challenges arisen in clinical trials and market reactions have been solved. Cost-effectiveness, quality and understanding of customer needs are the supremacy factors offered by Kaptas for its customers.
The Kaptas concept has been refined in order to function effectively from planning to realisation. Markets require rapid reaction to customer needs. Delivery time is one of Kaptas's absolute assets.
Kaptas as part of a value network
Finnish expertise in intelligent automation, robotics and artificial intelligence is already globally utilised in the pharmaceutical industry.
The North Karelian ecosystem benefiting the pharmaceutical industry is based on expertise, attitude, cooperation and ability to understand the entity from a customer's viewpoint.
Subcontractor industry in the service of the international pharmaceutical industry is part of health technology, around which a remarkably strong value network has been created in Norh Karelia.
Kaptas Oy is a central actor in the ecosystem, which includes Phillips Medisize, Valukumpu, Muovisola, Muottituote, Thermo Fischer and Medix Biochemica in North Karelia.
The North Karelian expertise cluster forms an important part of the Finnish innovative entity in the health industry. The ecosystem benefiting the pharmaceutical industry is based on expertise, attitude, cooperation and ability to understand the entity from a customer's viewpoint.